JF
DFTX

Jump Financial’s Definium Therapeutics DFTX Stock Holding History

Jump Financial’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-36,826
Closed -$135K – 2145
2023
Q4 		$135K Buy
36,826
+2,826
+8% +$8.51K ﹤0.01% 1629
2023
Q3 		$106K Buy
+34,000
New +$140K ﹤0.01% 1669

Other funds holding DFTX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Jump Financial's DFTX Position: Q1 2024 in Review

Jump Financial sold out of Definium Therapeutics (DFTX) in Q1 2024, closing a stake of 36,826 shares — an estimated $135K sold.

Jump Financial first reported a position in DFTX in Q3 2023 and held it in 2 quarters. The position peaked at $135K in Q4 2023. 135 funds tracked by Wall St. Rank hold DFTX as of Q1 2024.

  • Jump Financial reported no remaining Definium Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Jump Financial sold 36,826 Definium Therapeutics shares in Q1 2024, an estimated $135K.
  • Jump Financial first reported a position in Definium Therapeutics in Q3 2023 and held it in 2 quarters.
  • Jump Financial's Definium Therapeutics position peaked at $135K in Q4 2023.
  • 135 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2024.

Based on Jump Financial's 13F filing for Q1 2024, filed 13 May 2024.